CN101602680B - Naphthyl ethylamine derivative and preparation method thereof and application of naphthyl ethylamine derivative in preparing weight-reducing medicament - Google Patents
Naphthyl ethylamine derivative and preparation method thereof and application of naphthyl ethylamine derivative in preparing weight-reducing medicament Download PDFInfo
- Publication number
- CN101602680B CN101602680B CN 200910115507 CN200910115507A CN101602680B CN 101602680 B CN101602680 B CN 101602680B CN 200910115507 CN200910115507 CN 200910115507 CN 200910115507 A CN200910115507 A CN 200910115507A CN 101602680 B CN101602680 B CN 101602680B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- ethylamine derivative
- naphthyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 20
- RUJHATQMIMUYKD-UHFFFAOYSA-N 2-naphthalen-1-ylethanamine Chemical class C1=CC=C2C(CCN)=CC=CC2=C1 RUJHATQMIMUYKD-UHFFFAOYSA-N 0.000 title abstract 5
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000003513 alkali Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical group 0.000 claims description 38
- WJVGMHDMWXHVFE-UHFFFAOYSA-N ethanamine;naphthalene Chemical class CCN.C1=CC=CC2=CC=CC=C21 WJVGMHDMWXHVFE-UHFFFAOYSA-N 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 8
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 claims description 6
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 claims description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 238000006114 decarboxylation reaction Methods 0.000 claims description 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 7
- 229910052736 halogen Inorganic materials 0.000 abstract description 4
- 125000003118 aryl group Chemical group 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000010025 steaming Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- -1 [1-(7-methoxy-1-naphthyl) cyclobutyl] methylamine Chemical compound 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003810 ethyl acetate extraction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 239000008098 formaldehyde solution Substances 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- PYJMGUQHJINLLD-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)acetonitrile Chemical compound C1=CC=C(CC#N)C2=CC(OC)=CC=C21 PYJMGUQHJINLLD-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 0 *C(C1(CCC1)c1cccc2ccccc12)N(*)* Chemical compound *C(C1(CCC1)c1cccc2ccccc12)N(*)* 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MGJHVZKRAOYORH-UHFFFAOYSA-N 2-(7-methoxy-3,4-dihydronaphthalen-1-yl)acetonitrile Chemical compound C1CC=C(CC#N)C2=CC(OC)=CC=C21 MGJHVZKRAOYORH-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- MUZZFWWKQIYSPV-UHFFFAOYSA-N N#CCC1=CCCc2ccccc12 Chemical compound N#CCC1=CCCc2ccccc12 MUZZFWWKQIYSPV-UHFFFAOYSA-N 0.000 description 1
- LVQXAJAUPOJPIA-UHFFFAOYSA-N N-[[1-(7-methoxynaphthalen-1-yl)cyclobutyl]methyl]acetamide Chemical compound C12=CC(OC)=CC=C2C=CC=C1C1(CNC(C)=O)CCC1 LVQXAJAUPOJPIA-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Abstract
The invention discloses a naphthyl ethylamine derivative and a preparation method thereof and application of the naphthyl ethylamine derivative in preparing medicaments for treating obesity. The naphthyl ethylamine derivative is characterized in that the composition exists in a form of alkali or pharmaceutical salt, and has the general structural formula shown in the formula (I), wherein R is halogen, halogenated methyl radical, nitryl or optionally-substituted C1 to C3 alkoxy; R1 and R2 are H, optionally-substituted C1 to C6 alkyl or a substituent group of which the structure is shown in general formula (II); in the formula (II), R4 is the H, aryl, or optional C1 to C6 alkyl or C1 to C3 alkoxy; and the R3 is the optionally-substituted C1 to C6 alkyl. Pharmacological tests prove that the composition has good function of treating the obesity.
Description
Technical field
The invention belongs to the medicine pharmaceutical technology field of obesity, relate to a kind of derivative with naphthalene ethylamine of antiobesity action, this invention has also related to preparation method and the application aspect the medicine of preparation treatment of obesity of this derivative.
Background technology
Obesity has become ubiquitous problem in countries in the world, various crowd.Studies show that obesity is closely related with diseases such as hypertension, coronary heart disease, apoplexy, type ii diabetes, can increase the M ﹠ M of these diseases.Therefore obesity more and more causes people's attention, and the medicine of developing treatment of obesity safe, effective, easy to use seems more and more important.
The medicine of at present treatment obesity comprises following a few class according to its mechanism of action.A kind of is appetite-inhibiting agent, and Main Function is in central nervous system with depress appetite or increase satietion.These medicines comprise phentermine, Diethylpropion etc., because there is potential cardiovascular adverse effects in it, use now less.Metabolism Reinforcing agent by strengthening the metabolic function of Digestive tract, reduces the deposit of energy and fat, if this class drug main thyroid hormone formulations, because its cardiovascular side effects is used gradually less.
Other two kinds of more medicines of application are thrombotonin and NRI and lipase inhibitor.Typical lipase inhibitor such as orlistat structure are similar with triglyceride level, by competitive inhibition, make the absorption of triglyceride level reduce 30% and discharge from ight soil with original shape, minimizing energy intake and reach the purpose of fat-reducing.Yet, this medicine owing in the ight soil fat be steatorrhea, mashed just.What thrombotonin and NRI application were more is sibutramine, the maincenter that acts on strengthens full sense, make the minimizing of ingesting, and pass through adrenergic receptor and promote thermogenesis, make and lose weight, although also have some such as untoward reactions such as nauseating, dry, constipation, yet because determined curative effect becomes comparatively widely used slimming medicine.
Sibutramine slimming medicine commonly used is Sibutramine hydrochloride, be N-{1-[1-(4 mono chloro benzene base) cyclobutyl]-the 3-methyl butyl }-N, N-dimethyl amine hydrochloride, it mainly is to suppress norepinephrine and 5-HT re-uptake, improves these mediators concentration in maincenter, produces the excitation of maincenter sympathetic nervous system, suppress feeding center, reduce feed; Can increase simultaneously glucose utilization and the calorigenic action of fatty tissue, increase energy expenditure, reduce body weight, thereby reach the fat purpose for the treatment of.Yet because the kind of application antiobesity agents is fewer, and the effect of fat-reducing can not satisfy increasing obese patient's needs far away, the present invention comes therefrom in the actual life.
Summary of the invention
The object of the invention is to provide a kind of brand-new structural compounds---naphthalene ethylamine derivative, as the medicine of new treatment of obesity, solved in the prior art obesity treating medicine select limited, the unconspicuous defective of curative effect.
In order to solve these problems of the prior art, technical scheme provided by the invention is:
A kind of naphthalene ethylamine derivative is characterized in that described compound exists with alkali or pharmacologically acceptable salt formation, and has the general structure of formula (I):
Wherein, R is selected from halogen, halogenated methyl, nitro or the optional C that replaces
1～C
3Alkoxyl group; R
1, R
2Be selected from H, the optional C that replaces
1～C
6Alkyl or the substituted radical of structure with general formula (II):
Wherein, R
4Be selected from H, aryl, optional C
1～C
6Alkyl or C
1～C
3Alkoxyl group;
R
3Be selected from the optional C that replaces
1～C
6Alkyl.
Preferably, R in the described naphthalene ethylamine derivative general formula (I)
1, R
2Be selected from H, the optional C that replaces
1～C
6Alkyl, and R
1, R
2Identical.
Preferably, R in the general formula of described naphthalene ethylamine derivative (I)
1Be selected from the substituted radical that structure has general formula (II):
Wherein, R
4Be selected from H, aryl, optional C
1～C
6Alkyl or C
1～C
3Alkoxyl group; R
2Be selected from H.
Preferably, the pharmaceutical acceptable salt of compound is selected from hydrochloride, vitriol, phosphoric acid salt or mesylate.
Another object of the present invention provides a kind of preparation method of naphthalene ethylamine derivative, it is characterized in that said method comprising the steps of:
(1) the following structural formula (III) of an amount of mole proportioning
Compound and cyanoacetic acid under the condition that benzyl ammonia and enanthic acid exist, add the thermal condensation decarboxylation and obtain formula (IV)
(2) compound and the dichlorodicyanobenzoquinone dehydrogenation reaction that obtain of step (1) obtains formula (V)
(3) compound and 1, the 3 dihalopropane cyclization that obtain of step (2) obtains formula (VI)
Wherein R is selected from halogen, halogenated methyl, nitro or the optional C that replaces
1～C
3Alkoxyl group;
(4) the compound generation cyanogen solution reaction that step (3) is obtained obtains the compound of formula (I).
Preferably, the cyanogen solution reactions steps of described step (4) comprising:
A, compound and halogenated alkane that step (3) is obtained react the compound that obtains formula (VII);
B, compound and sodium borohydride that steps A is obtained react the compound that obtains formula (VIII) under the condition that acetic acid exists;
C, compound and suitable acid-respons that step B is obtained obtain the compound of formula (VI);
Wherein R is selected from halogen, halogenated methyl, nitro or the optional C that replaces
1～C
3Alkoxyl group; R
3Be selected from the optional C that replaces
1～C
6Alkyl.
The present invention, replaces its phenyl ring with naphthalene nucleus, and structural modification is carried out at some other position as Research foundation with the structure of Sibutramine hydrochloride, wonderfully obtains a series of naphthalene ethylamine derivatives that can carry out effective antiobesity action.
The synthetic method route of naphthalene ethylamine derivative of the present invention is as follows:
Another purpose of the present invention has been to provide the application of a kind of naphthalene ethylamine derivative in the preparation obesity treating medicine.
If naphthalene ethylamine derivative of the present invention contains the optical activity carbon atom, the present invention also provides enantiomorph or its mixture of these compounds.
Naphthalene ethylamine derivative of the present invention is when existing with pharmaceutical acceptable salt, and described salt is preferably the salt of following acid: Hydrogen bromide, sulfuric acid, methylsulfonic acid, formic acid, acetic acid, oxalic acid, succsinic acid, tartrate, amygdalic acid, fumaric acid, lactic acid, hydrochloric acid, citric acid, phosphoric acid, L-glutamic acid and/or aspartic acid.
And, wonderful discovery, derivative of the present invention has the biological activity for the treatment of of obesity; Particularly preferred pharmaceutical composition comprises that the salt of naphthalene ethylamine derivative or these compounds is as active substance, these active substances are selected from [1-(7-methoxy-1-naphthyl) cyclobutyl] methylamine, 1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-N, N-dimethyl methylamine, N-{[1-(7-methoxy-1-naphthyl) cyclobutyl] methyl } ethanamide, N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-2-methyl propylamine, N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-2-methyl-propyl-N, N dimethylamine, N-{[1-(7-methoxy-1-naphthyl) cyclobutyl]-the 2-methyl-propyl } ethanamide, N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-the 3-methylbutylamine, N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-3-methyl butyl-N, N dimethylamine, N-{[1-(7-methoxy-1-naphthyl) cyclobutyl]-the 3-methyl butyl } ethanamide.
For preparing corresponding pharmaceutical composition, except at least a active substance of the present invention, also use solid support material, filler, solvent, thinner, tinting material or binding agent.The selection of auxiliary agent and consumption thereof depend on the route of administration of this medicine, use such as in oral, intravenous injection, abdominal injection, intracutaneous, muscle, the nose or part.The preparation of the forms such as tablet, coating tablet, capsule, granule, drops, liquid dosage form and syrup is suitable for oral, and solution, suspension agent, sprays etc. are applicable to non-enteron aisle, part and inhalation.Give patient or laboratory animal dosage body weight, method of application according to patient or animal, refer to disease and the administration of illness situation.
The present invention is with respect to medicine scheme of the prior art, and advantage of the present invention is:
Confirm that through experimentation on animals the pharmaceutical composition of naphthalene ethylamine derivative provided by the invention has good fat-reducing and antihyperglycemic.
Embodiment
Below in conjunction with specific embodiment such scheme is described further.Should be understood that these embodiment are not limited to limit the scope of the invention for explanation the present invention.The implementation condition that adopts among the embodiment can be done further adjustment according to the condition of concrete producer, and not marked implementation condition is generally the condition in the normal experiment.
The preparation of embodiment 1 pharmaceutical intermediate of the present invention
Synthesizing of (7-methoxyl-3,4-dihydro-1-naphthyl) acetonitrile:
7-methoxyl group naphthane-1-ketone (17.6g, 0.1mol), cyanoacetic acid (12.8g, 0.15mol), benzylamine (2.7g, 25mmol), enanthic acid (3.3g, 25mmol) drop in the toluene (160ml), reflux water-dividing 24 hours, be cooled to room temperature, reaction solution is used 2mol/L sodium hydroxide solution (60ml), water (60ml) and saturated aqueous common salt (60ml) washing successively, use anhydrous sodium sulfate drying, filter, filtrate is steamed except toluene, get oily matter (18.9g, 95%).
Synthesizing of (7-methoxy-1-naphthyl) acetonitrile:
DDQ (25g, 0.11mol) drop in the dry methylene dichloride (200ml), 20 ℃ of lower above-mentioned oily matter (20g that drip, 0.1mol) dichloromethane solution (100ml), dripped complete insulated and stirred 1 hour, reacting liquid filtering, filtrate is used saturated sodium bicarbonate solution (100ml * 3), water (100ml), saturated aqueous common salt (100ml) washing successively, use anhydrous sodium sulfate drying, filter filtrate steaming removal solvent, residuum alcohol-water (5: 3) recrystallization, oven dry gets pale powder (18.6g, 94%).
Synthesizing of 1-(7-methoxyl group naphthyl) cyclobutyronitrile:
With (7-methoxy-1-naphthyl) acetonitrile (16.6g, 0.083mol) and 1,3 dibromopropane (18.2g, 0.091mol) be dissolved in the 60ml methyl-sulphoxide, descend in the aaerosol solution of the 120ml methyl-sulphoxide that this solution is slowly splashed into 18.6 potassium hydroxide (fine powder) in 20～25 ℃ of abundant stirrings.Drip and finish, continue to stir 1h, reactant is cooled under 15 ℃, drip frozen water 150ml, keep simultaneously temperature to be no more than 20 ℃.With this solution of ethyl acetate extraction (80ml * 3), combined ethyl acetate, respectively water (100ml), saturated aqueous common salt (100ml) washing, anhydrous sodium sulfate drying, filter, filtrate steaming removal solvent gets orange red oily matter, with ethyl acetate-sherwood oil (1: 1) recrystallization, dry to get faint yellow solid (14g, 70%).
1H-NMR(δ，ppm，d-DMSO)：2.16(m，2H)；2.72(t，2H)；2.93(t，2H)；3.99(s，3H)；7.12～7.89(m，6H)
The preparation of embodiment 2 the present invention [1-(7-methoxy-1-naphthyl) cyclobutyl] methylamine
Under the ice bath with 1-(7-methoxyl group naphthyl) cyclobutyronitrile (9.5g, 0.04mol), Nickel dichloride hexahydrate (9.5g, 0.04mol), the 30ml dehydrated alcohol joins in the 100ml eggplant-shape bottle, add sodium borohydride (4.6g under the vigorous stirring in batches, 0.12mol), the solution colour blackening finishes and continues to stir 30 minutes.Then slowly add the hydrochloric acid of 30ml concentration 4mol/L in the reaction solution, solution colour gradually becomes light green.Solution is concentrated to be steamed except ethanol, then removes by filter unreacted 1-(7-methoxyl group naphthyl) cyclobutyronitrile.Filtrate is regulated PH9～10 with sodium hydroxide, with this solution of ethyl acetate extraction (20ml * 3), combined ethyl acetate, respectively water (30ml), saturated aqueous common salt (30ml) washing, anhydrous sodium sulfate drying filters, and filtrate steaming removal solvent gets orange red oily matter (7.2g, 76%), salify.
1H-NMR(δ，ppm，d-DMSO)：2.10(m，2H)2.36～2.75(m，4H)；2.92(s，2H)；3.83(s，3H)；5.24(s，2H)7.02～7.89(m，6H)
Embodiment 3 1-[1-of the present invention (7-methoxy-1-naphthyl) cyclobutyl]-N, the preparation of N-dimethyl methylamine
Get [1-(7-methoxy-1-naphthyl) cyclobutyl] methylamine (2.4g, 0.01mol) in the 50ml eggplant-shape bottle, slowly 88% formic acid (15ml), 37% formaldehyde solution (5ml) are added wherein, refluxed one hour, drip again 37% formaldehyde (5ml), continue backflow 24h, be cooled to room temperature, pour in the 40ml frozen water, regulate about PH to 9～10 with 50% sodium hydroxide, with ethyl acetate extraction three times (20ml * 3), combined ethyl acetate, respectively water (30ml), saturated aqueous common salt (30ml) washing.Anhydrous sodium sulfate drying filters, and filtrate steaming removal solvent gets orange red oily matter (2.15g, 79.6%), salify.
1H-NMR(δ，ppm，d-DMSO)：2.01(m，2H)2.26(s，6H)；2.52～2.79(m，4H)2.63(s，2H)；3.76(s，3H)；7.10～7.75(m，6H)
Embodiment 4N-{[1-(7-methoxy-1-naphthyl) cyclobutyl] methyl } preparation of ethanamide
Get [1-(7-methoxy-1-naphthyl) cyclobutyl] methylamine (2.4g, 0.01mol) in the 50ml eggplant-shape bottle, add the 15ml diacetyl oxide in 40 ℃ of lower 1h of stirring.Cooling has solid to separate out to wherein adding 20ml water gradually, filters to get pale solid (2.6g, 92%).
1H-NMR(δ，ppm，d-DMSO)：1.79(s，3H)；2.11(m，2H)；2.75～3.02(m，4H)；3.47(s，2H)；3.93(s，3H)；7.12～7.97(m，6H)
Embodiment 5N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-preparation of 2-methyl propylamine
With 1-(7-methoxyl group naphthyl) cyclobutyronitrile (7.1g, 0.03mol) be dissolved in the 35ml dry toluene, this solution is splashed into { isopropyl bromide 11g (0.09mol), magnesium chips 3.24g (0.135mol), anhydrous diethyl ether 35ml} in the isopropyl magnesium bromide solution.During dropping, ether is removed by distillation.Rate of addition and distillation speed are about equally.Drip to finish, when treating interior temperature rise to 90 ℃, stop distillation, mixture continues to stir 12 hours.After the question response liquid cooling but, slowly dripping the 50ml saturated aqueous common salt under the ice bath is hydrolyzed, dropwise and continue to stir half an hour, filter, filtrate is told toluene layer, respectively water (40ml), saturated aqueous common salt (40ml) washing, anhydrous sodium sulfate drying, filter, filtrate steaming removal solvent gets orange red oily matter.
Above-mentioned oily matter is dissolved in the 40ml acetic acid, adds sodium borohydride (3.4g, 0.09mol) under the room temperature in batches, then continue stirring reaction half an hour.Slowly adding sodium hydrate solid under the ice bath regulates about PH to 9～10.Dichloromethane extraction (40ml * 3), combined dichloromethane be water (50ml), saturated aqueous common salt (50ml) washing respectively.Anhydrous sodium sulfate drying filters, and filtrate steaming removal solvent gets orange red oily matter (6.9g, 81%).The hydrochloric acid salify gets yellow solid, and ethyl alcohol recrystallization gets white powder.
1H-NMR(δ，ppm，d-DMSO)：0.88(d，6H)；1.82～2.04(m，1H)；1.98(m，2H)；2.63～2.90(m，4H)；2.97(d，1H)；3.90(s，3H)；5.60(s，2H)；7.08～7.94(m，6H)
Embodiment 6N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-2-methyl-propyl-N, the preparation of N dimethylamine
Get N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-2-methyl propylamine (2.8g, 0.01mol) in the 50ml eggplant-shape bottle, slowly with 88% formic acid (15ml), 37% formaldehyde solution (5ml) adds wherein, refluxed one hour, drip again 37% formaldehyde (5ml), continue backflow 24h, be cooled to room temperature, pour in the 40ml frozen water, regulate about PH to 9～10 with 50% sodium hydroxide, with ethyl acetate extraction three times (20ml * 3), combined ethyl acetate, difference water (30ml), saturated aqueous common salt (30ml) washing.Anhydrous sodium sulfate drying filters, and filtrate steaming removal solvent gets orange red oily matter (2.54g, 82%), salify.
1H-NMR(δ，ppm，d-DMSO)：0.92(d，6H)；1.76～1.89(m，1H)；2.06(m，2H)；2.30(s，6H)；2.68～2.94(m，4H)；2.85(d，1H)；3.83(s，3H)；7.12～7.97(m，6H)
Embodiment 7N-{[1-(7-methoxy-1-naphthyl) cyclobutyl]-the 2-methyl-propyl } preparation of ethanamide
Get N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-2-methyl propylamine (2.8g, 0.01mol) is in the 50ml eggplant-shape bottle, and adding 15ml diacetyl oxide is in 40 ℃ of lower 1h that stir.Cooling has solid to separate out to wherein adding 20ml water gradually, filters to get pale solid (2.83g, 88%).
1H-NMR(δ，ppm，d-DMSO)：1.00(d，6H)；1.84(s，3H)；2.11(m，2H)；2.45(m，1H)；2.36～2.78(m，4H)；3.94(d，1H)；3.98(s，3H)；7.22～7.88(m，6H)
Embodiment 8N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-preparation of 3-methylbutylamine
With 1-(7-methoxyl group naphthyl) cyclobutyronitrile (7.1g, 0.03mol) be dissolved in the 35ml dry toluene, this solution is splashed into { isobutyl bromide 12.15g (0.09mol), magnesium chips 3.24g (0.135mol), anhydrous diethyl ether 35ml} in the selenium alkynide solution.During dropping, ether is removed by distillation.Rate of addition and distillation speed are about equally. and drip to finish, when treating interior temperature rise to 90 ℃, stop distillation, mixture continues to stir 12 hours.After the question response liquid cooling but, slowly dripping the 50ml saturated aqueous common salt under the ice bath is hydrolyzed, dropwise and continue to stir half an hour, filter, filtrate is told toluene layer, respectively water (40ml), saturated aqueous common salt (40ml) washing, anhydrous sodium sulfate drying, filter, filtrate steaming removal solvent gets orange red oily matter.
Above-mentioned oily matter is dissolved in the 40ml acetic acid, adds sodium borohydride (3.4g, 0.09mol) under the room temperature in batches, then continue stirring reaction half an hour.Slowly adding sodium hydrate solid under the ice bath regulates about PH to 9～10.Dichloromethane extraction (40ml * 3), combined dichloromethane be water (50ml), saturated aqueous common salt (50ml) washing respectively.Anhydrous sodium sulfate drying filters, and filtrate steaming removal solvent gets orange red oily matter (6.76g, 76%).The hydrochloric acid salify gets yellow solid, and ethyl alcohol recrystallization gets white powder.
1H-NMR(δ，ppm，d-DMSO)：0.91～1.62(m，9H)；2.06(m，2H)；2.26～2.58(m，4H)；2.98(t，1H)；3.88(s，3H)；5.60(s，2H)；7.02～7.89(m，6H)
Embodiment 9N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-3-methyl butyl-N, the preparation of N dimethylamine
Get N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-3-methylbutylamine (2.97g, 0.01mol) in the 50ml eggplant-shape bottle, slowly with 88% formic acid (15ml), 37% formaldehyde solution (5ml) adds wherein, refluxed one hour, drip again 37% formaldehyde (5ml), continue backflow 24h, be cooled to room temperature, pour in the 40ml frozen water, regulate about PH to 9～10 with 50% sodium hydroxide, with ethyl acetate extraction three times (20ml * 3), combined ethyl acetate, difference water (30ml), saturated aqueous common salt (30ml) washing.Anhydrous sodium sulfate drying filters, and filtrate steaming removal solvent gets orange red oily matter (2.6g, 80%), salify.
1H-NMR(δ，ppm，d-DMSO)：0.98～1.54(m，9H)；2.06(m，2H)；2.32～2.66(m，4H)；2.18(s，6H)；3.02(t，1H)；3.78(s，3H)；7.18～8.02(m，6H)
Embodiment 10N-{[1-(7-methoxy-1-naphthyl) cyclobutyl]-the 3-methyl butyl } preparation of ethanamide
Get N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-3-methylbutylamine (2.97g, 0.01mol) is in the 50ml eggplant-shape bottle, and adding 15ml diacetyl oxide is in 40 ℃ of lower 1h that stir.Cooling has solid to separate out to wherein adding 20ml water gradually, filters to get pale solid (2.86g, 84%).
1H-NMR(δ，ppm，d-DMSO)：0.92～1.60(m，9H)；1.85(s，3H)；2.12～2.59(m，6H)；3.82(s，3H)；4.02(t，1H)；7.17～7.94(m，6H)；8.30(s，1H)
The experiment of embodiment 11 pharmacological activities
Choose N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl that embodiment 9 obtains]-3-methyl butyl-N, N dimethylamine is as target compound, by confirm the pharmacologically active of this compounds for treating obesity with following experiment.
Copying and medication of rat alimentary obesity model:
72 of the SD rats of just ablactation are divided into 6 groups (n=12) at random, the Normal group normal diet of feeding, all the other rats nutritional feed of feeding.The composition of nutritional feed: every 1000g basal feed is with milk powder 100g, lard 100g, and 10 in egg, 100 of cleum jecoris piscis concentratums (contain vitamin A 1.7 * 105U, vitamins D 1.7 * 104U), an amount of fresh soybean sprout of feeding every day.The administration of dividing into groups behind the 7kw, Normal group (5g/L CMC-Na solution), model control group (5g/L CMC-Na solution), Sibutramine hydrochloride group (8mg/kg), target compound high dose group (30mg/kg), middle dosage group (10mg/kg), low dose group (3.0mg/kg).Gastric infusion, capacity are the 5ml/kg body weight, and every day 1 time, 6wk obtains following pharmacology result, such as table 1, table 2 continuously.
Table 1 is on the impact of rat body weight: (mean body weight/g, n=12)
Table 2 is on the impact of rat height, Lee ' s index, fat weight: (x ± s, n=12)
Compare with model control group:
aP＜0.05,
bThere is the statistics difference p＜0.01,
cP＞0.05 is without the statistics difference
Above-mentioned experiment shows: target compound N-1-[1-(7-methoxy-1-naphthyl) cyclobutyl]-3-methyl butyl-N, N dimethylamine has certain fat-reducing and antihyperglycemic to nutritive obesity in rats when dosage is higher.
Above-mentioned example only is explanation technical conceive of the present invention and characteristics, and its purpose is to allow the people who is familiar with technique can understand content of the present invention and according to this enforcement, can not limit protection scope of the present invention with this.All equivalent transformations that spirit is done according to the present invention or modification all should be encompassed within protection scope of the present invention.
Claims (6)
1. naphthalene ethylamine derivative is characterized in that described compound forms with alkali or pharmacologically acceptable salt to exist, and has the general structure of formula (I):
Wherein, R is selected from C
1～C
3Alkoxyl group; R
1, R
2Be selected from respectively H, C
1～C
6Alkyl;
R
3Be selected from C
1～C
6Alkyl.
2. naphthalene ethylamine derivative according to claim 1 is characterized in that R in the described naphthalene ethylamine derivative general formula (I)
1, R
2Be selected from respectively H, C
1～C
6Alkyl, and R
1, R
2Identical.
3. naphthalene ethylamine derivative according to claim 1 is characterized in that the pharmaceutical acceptable salt of compound is selected from hydrochloride, vitriol, phosphoric acid salt or mesylate.
4. the preparation method of a naphthalene ethylamine derivative claimed in claim 1 is characterized in that said method comprising the steps of:
(1) the following structural formula (III) of an amount of mole proportioning
Compound and cyanoacetic acid under the condition that benzyl ammonia and enanthic acid exist, add the thermal condensation decarboxylation and obtain formula (IV)
(2) compound and the dichlorodicyanobenzoquinone dehydrogenation reaction that obtain of step (1) obtains formula (V)
Compound;
(3) compound and 1, the 3 dihalopropane cyclization that obtain of step (2) obtains formula (VI)
Compound;
Wherein R is selected from C
1～C
3Alkoxyl group;
(4) the compound generation cyanogen solution reaction that step (3) is obtained obtains the compound of formula (I).
5. method according to claim 4 is characterized in that the cyanogen solution reactions steps of described step (4) comprising:
A, compound and halogenated alkane that step (3) is obtained react the compound that obtains formula (VII);
B, compound and sodium borohydride that steps A is obtained react the compound that obtains formula (VIII) under the condition that acetic acid exists;
C, compound and suitable acid-respons that step B is obtained obtain the compound of formula (VI);
Wherein R is selected from C
1～C
3Alkoxyl group R
3Be selected from C
1～C
6Alkyl.
6. the application of naphthalene ethylamine derivative claimed in claim 1 in the preparation obesity treating medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910115507 CN101602680B (en) | 2009-06-08 | 2009-06-08 | Naphthyl ethylamine derivative and preparation method thereof and application of naphthyl ethylamine derivative in preparing weight-reducing medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910115507 CN101602680B (en) | 2009-06-08 | 2009-06-08 | Naphthyl ethylamine derivative and preparation method thereof and application of naphthyl ethylamine derivative in preparing weight-reducing medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101602680A CN101602680A (en) | 2009-12-16 |
| CN101602680B true CN101602680B (en) | 2013-04-24 |
Family
ID=41468599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910115507 Active CN101602680B (en) | 2009-06-08 | 2009-06-08 | Naphthyl ethylamine derivative and preparation method thereof and application of naphthyl ethylamine derivative in preparing weight-reducing medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101602680B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104292126B (en) * | 2014-08-14 | 2016-08-24 | 广东东阳光药业有限公司 | Naphthalene derivatives and the application on medicine thereof |
| CN106543034A (en) * | 2016-10-31 | 2017-03-29 | 苏州弘森药业股份有限公司 | A kind of method of 7 methoxynaphthalene acetonitriles of synthesis |
| CN107151221A (en) * | 2017-06-19 | 2017-09-12 | 太仓卡斯特姆新材料有限公司 | A kind of method for preparing the methoxynaphthalene acetonitrile of agomelatine important intermediate 7 |
| CN107353229B (en) * | 2017-08-08 | 2019-04-30 | 许昌恒生制药有限公司 | A kind of preparation method of agomelatine intermediate body |
| CN110066221B (en) * | 2019-05-16 | 2022-03-08 | 海门瑞一医药科技有限公司 | Preparation method of cyclopropylmethylamine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557802A (en) * | 2004-01-13 | 2004-12-29 | 苏州市玮琪生物科技有限公司 | Sibutramine aromatic salt of organic acid and its preparation process |
-
2009
- 2009-06-08 CN CN 200910115507 patent/CN101602680B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557802A (en) * | 2004-01-13 | 2004-12-29 | 苏州市玮琪生物科技有限公司 | Sibutramine aromatic salt of organic acid and its preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101602680A (en) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5232946A (en) | Phenylethanolamines, their use as pharmaceuticals and as performance enhancers in animals | |
| JP3950337B2 (en) | Malignant tumor treatment | |
| CN101602680B (en) | Naphthyl ethylamine derivative and preparation method thereof and application of naphthyl ethylamine derivative in preparing weight-reducing medicament | |
| JP2019516795A (en) | (S) -N- (5-((R) -2- (2,5-difluorophenyl) pyrrolidin-1-yl) -pyrazolo [1,5-a] pyrimidin-3-yl) -3-hydroxypyrrolidine Preparation of -1-carboxamide | |
| WO1994014780A1 (en) | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors | |
| EP2802320B1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| CN1253551A (en) | Pyrazine compounds | |
| PL112937B1 (en) | Method of manufacture of novel aminoalkylheterocyclic compounds | |
| GB2106105A (en) | Benzo-heterocycles | |
| US20080119477A1 (en) | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | |
| CN101223129A (en) | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof | |
| JP5014332B2 (en) | Use of non-steroidal androgen receptor agonists, compounds in their preparation or pharmaceutically acceptable salts thereof | |
| EP0047536B1 (en) | Substituted propylamines | |
| CN115304590A (en) | 2H-benzotriazole derivatives, preparation method thereof and pharmaceutical composition containing same | |
| US20220389006A1 (en) | Salts and forms of an estrogen receptor modulator | |
| TW202024038A (en) | Small molecules targeting mutant mammalian proteins | |
| CN1198822C (en) | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | |
| US7595340B2 (en) | Serotonin and norepinephrine reuptake inhibitor and uses thereof | |
| TW302355B (en) | ||
| US5026702A (en) | Morpholines and morpholine-N-oxides and pharmaceutical compositions containing these compounds | |
| JP2005538146A (en) | Novel piperidine-2,6-dione pamoate salts and methods for using them to treat and treat stress-related emotional disorders | |
| JP2005502677A (en) | Novel piperidine-2,6-dione bisulfates and methods of using them to treat and treat stress-related emotional disorders. | |
| US3950335A (en) | 1-(3'-trifluoromethyl-4'-chloro-phenyl)-2-amino-propanes and salts thereof | |
| US11851413B1 (en) | 1,3-benzothiazol-2-yl-N'-[(naphthalene-1-carbonyl)oxy]ethanimidamide as an antitumor and antimicrobial compound | |
| CN101314591B (en) | Novel pyrazoles highly-selective marijuana acceptor-1antagon and/or reversed activation agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231019 Address after: 215000, 1st, 2nd, and 3rd floors of Building 2 (South Building), Jinsigang Industrial Community, Guoxiang Street, Wuzhong District, Suzhou City, Jiangsu Province Patentee after: SUZHOU KARY NANO TECHNOLOGY Co.,Ltd. Address before: 215123 Jiangsu Province, Suzhou City Industrial Park Xinghu street BioBAY A3 building 4 floor Patentee before: SUZHOU CHIREACH BIOMEDICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |